Abstract: A method for assessing a cancer status of biological tissue includes the steps of: obtaining a Raman spectrum indicating a Raman spectroscopy response of the biological tissue, the Raman spectrum captured using a fiber-optic probe of a fiber-optic Raman spectroscopy system; inputting the Raman spectrum into a boosted tree classification algorithm of a computer program, and using the boosted tree classification algorithm for comparing, in real-time, the captured Raman spectrum to reference data and assessing the cancer status of the biological tissue based on said comparison, the reference data being previously determined based on a set of reference Raman spectra indicating Raman spectroscopy responses of reference biological tissues wherein each of the reference biological tissues is associated with a known cancer status; and generating a real-time output indicating the assessed cancer status of the biological tissue,

Abstract: A method for assessing a cancer status of biological tissue includes the steps of: obtaining a Raman spectrum indicating a Raman spectroscopy response of the biological tissue, the Raman spectrum captured using a fiber-optic probe of a fiber-optic Raman spectroscopy system; inputting the Raman spectrum into a boosted tree classification algorithm of a computer program, and using the boosted tree classification algorithm for comparing, in real-time, the captured Raman spectrum to reference data and assessing the cancer status of the biological tissue based on said comparison, the reference data being previously determined based on a set of reference Raman spectra indicating Raman spectroscopy responses of reference biological tissues wherein each of the reference biological tissues is associated with a known cancer status; and generating a real-time output indicating the assessed cancer status of the biological tissue.

Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.

Abstract: The biopsy device generally comprises: a cannula body having a longitudinal axis and a probing region extending along the longitudinal axis, the probing region having a sample receiving window defined therein for receiving a sample of a surrounding tissue when performing a biopsy; and a plurality of optical fibers mounted along an exterior portion of the cannula body, each of the plurality of optical fibers having a fiber end in the probing region of the cannula body, at least one of the plurality of optical fibers being adapted to illuminate the surrounding tissue with an optical signal generated by the at least one light generator and at least one of the plurality of optical fibers being adapted to detect an optical signal response with the at least one light detector, the optical signal response being caused by the propagation of the optical signal in the surrounding tissue.

Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.

Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.

Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.